Standard treatments for HIV, Spring 1997. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Standard treatments for HIV, Spring 1997. Clearinghouse, AIDS Newsletter Database, P.O. Box 6003, Rockville, MD 20849-6003. 800-458-5231 ext. 5714. A fee will apply.

AIDS Treat News. 1997 Apr 18;(No 269):4-5. Unique Identifier : AIDSLINE AIDS/97702543
Smith D


Abstract: Current treatment standards dictate combination anti-HIV therapy. A brief guide to antiretroviral drugs, including reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors that are approved by the Food and Drug Administration (FDA) is given. The importance of compliance with drug regimens is stressed, and all treatments should be to minimize the viral load to undetectable levels.
Keywords: *Anti-HIV Agents/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ THERAPEUTIC USE Antineoplastic Agents/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ THERAPEUTIC USE Drug Therapy, Combination HIV Infections/*DRUG THERAPY *HIV Protease Inhibitors/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/ THERAPEUTIC USE Human Hydroxyurea/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/THERAPEUTIC USE *Reverse Transcriptase Inhibitors/ADMINISTRATION & DOSAGE/ADVERSE EFFECTS/THERAPEUTIC USE NEWSLETTER ARTICLEKWDanti-hivagents/administration&dosage/adverseeffects/therapeuticuseantineoplasticagents/administration&dosage/adverseeffects/therapeuticusedrugtherapy,combinationhivinfections/KWDdrugtherapyKWDhivproteaseinhibitors/administration&dosage/adverseeffects/therapeuticusehumanhydroxyurea/administration&dosage/adverseeffects/therapeuticuseKWDreversetranscriptaseinhibitors/administration&dosage/adverseeffects/therapeuticusenewsletterarticle
970830
M9781208

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .